Mesa Laboratories Inc. (MLAB)
Nasdaq · Industrial Instruments For Measurement, Display, And Control · Manufacturing · CIK 724004 · fiscal year ends in Mar
Closing price $132.96 on 29 Oct 2026; 52-week range $70.60 to $142.52.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $249.7M
- Revenue growth
- 3.0%
- Net income, last twelve months
- $4.8M
- Earnings per share
- $0.84
- Gross margin
- 64.2%
- Operating margin
- 9.0%
- Net margin
- 1.9%
- Free cash flow
- $52.9M
- Return on equity
- 2.5%
- Market value
- $744.0M
- Price to earnings
- 158.3x
- Dividend yield
- 0.5%
- Cash
- $30.7M
- Debt
- $142.9M
- Debt to equity
- 0.76
- Shares outstanding
- 5.6M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2026 | 31 Mar 2026 | $249.1M | $18.5M | $6.7M | $1.21 | $39.6M | 10-K filed 3 Jun 2026 |
| FY2025 | 31 Mar 2025 | $241.0M | $16.3M | -$2.0M | -$0.36 | $42.6M | 10-K filed 28 May 2025 |
| FY2024 | 31 Mar 2024 | $216.2M | -$272.1M | -$254.2M | -$47.20 | $41.6M | 10-K filed 28 Jun 2024 |
| FY2023 | 31 Mar 2023 | $219.1M | $3.3M | $930.0K | $0.17 | $23.4M | 10-K filed 30 May 2023 |
| FY2022 | 31 Mar 2022 | $184.3M | $4.7M | $1.9M | $0.35 | $34.8M | 10-K filed 31 May 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q1 FY2027 | 30 Jun 2026 | $60.1M | $2.8M | $0.49 |
| Q4 FY2026 | 31 Mar 2026 | $63.7M | -$4.1M | -$0.75 |
| Q3 FY2026 | 31 Dec 2025 | $65.1M | $3.6M | $0.65 |
| Q2 FY2026 | 30 Sep 2025 | $60.7M | $2.5M | $0.45 |
| Q1 FY2026 | 30 Jun 2025 | $59.5M | $4.7M | $0.85 |
| Q4 FY2025 | 31 Mar 2025 | $62.1M | -$7.1M | -$1.31 |
| Q3 FY2025 | 31 Dec 2024 | $62.8M | -$1.7M | -$0.31 |
| Q2 FY2025 | 30 Sep 2024 | $57.8M | $3.4M | $0.63 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2026
| Segment | Revenue | Share |
|---|---|---|
| Sterilization and Disinfection Control | $101.6M | 40.8% |
| Calibration Solutions | $53.6M | 21.5% |
| Biopharmaceutical Development | $48.6M | 19.5% |
| Clinical Genomics | $45.4M | 18.2% |
By product, FY2026
| Segment | Revenue | Share |
|---|---|---|
| Product | $203.4M | 81.6% |
| Service | $45.7M | 18.4% |
By region, FY2026
| Segment | Revenue | Share |
|---|---|---|
| United States | $116.9M | 46.9% |
| Other | $111.8M | 44.9% |
| China | $20.4M | 8.2% |
Company events
The newest 8-K filings of 223 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 13 Oct 2026 | 8-K | Restructuring, Investor update | 2.05, 7.01, 9.01 |
| 8 Sep 2026 | 8-K | Shareholder vote | 5.07 |
| 10 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Jul 2026 | 8-K | Code of ethics change | 5.05, 9.01 |
| 15 Jun 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 27 May 2026 | 8-K | Results | 2.02, 9.01 |
| 23 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 9 Mar 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 3 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 25 Aug 2025 | 8-K | Shareholder vote | 5.07 |
| 18 Aug 2025 | 8-K | New debt | 2.03, 9.01 |
Every filing
The newest filings with the SEC of 491 held.
| Filed | Form | Period |
|---|---|---|
| 13 Oct 2026 | 8-K | 12 Oct 2026 |
| 8 Sep 2026 | 8-K | 8 Sep 2026 |
| 10 Aug 2026 | 10-Q | 30 Jun 2026 |
| 10 Aug 2026 | 8-K | 10 Aug 2026 |
| 30 Jul 2026 | 8-K | 30 Jul 2026 |
| 22 Jul 2026 | DEF 14A | 8 Sep 2026 |
| 15 Jun 2026 | 8-K | 11 Jun 2026 |
| 3 Jun 2026 | S-8 | – |
| 3 Jun 2026 | 10-K | 31 Mar 2026 |
| 27 May 2026 | 8-K | 27 May 2026 |
| 23 Mar 2026 | 8-K | 20 Mar 2026 |
| 9 Mar 2026 | 8-K | 3 Mar 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 13 Aug 2026 | Sullivan John James, Director | Sale outside a trading plan | 7,093 | $112.80 | $800.1K | 17,834 | 17 Aug 2026 |
| 13 Aug 2026 | Kadia Siddhartha, President and CEO | Purchase | 7,093 | $112.80 | $800.1K | 7,093 | 17 Aug 2026 |
| 13 Aug 2026 | Tripeny R Tony, Director | Purchase | 900 | $113.69 | $102.3K | 6,298 | 17 Aug 2026 |
| 22 Jun 2026 | Crennen Lyndsey Elizabeth, CAO | Sale outside a trading plan | 442 | $89.50 | $39.6K | 2,020 | 23 Jun 2026 |
| 22 Jun 2026 | Archbold Brian David, SVP Operations | Sale outside a trading plan | 2,516 | $89.50 | $225.2K | 6,377 | 23 Jun 2026 |
| 22 Jun 2026 | Sakys John, CFO | Sale outside a trading plan | 2,827 | $89.50 | $253.0K | 19,785 | 23 Jun 2026 |
| 16 Jun 2026 | Archbold Brian David, SVP Operations | Sale under a trading plan | 1,151 | $101.27 | $116.6K | 3,710 | 17 Jun 2026 |
| 16 Jun 2026 | Crennen Lyndsey Elizabeth, CAO | Sale under a trading plan | 118 | $101.27 | $11.9K | 1,473 | 17 Jun 2026 |
| 16 Jun 2026 | Sakys John, CFO | Sale under a trading plan | 1,223 | $101.27 | $123.8K | 16,538 | 17 Jun 2026 |
| 10 Mar 2026 | Ladiwala Shiraz Shabanali, Director | Purchase | 3,500 | $72.23 | $252.8K | 8,523 | 10 Mar 2026 |
| 10 Mar 2026 | Capone Mark Christopher, Director | Purchase | 1,301 | $76.35 | $99.3K | 3,429 | 10 Mar 2026 |
| 10 Mar 2026 | Tripeny R Tony, Director | Purchase | 1,315 | $76.00 | $99.9K | 5,398 | 10 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 27 Aug 2026 | Owens Gary M, Former Officer | 20,358 | $2.6M | 27 Aug 2026 |
| 21 Aug 2026 | Owens Gary M, Former Officer | 20,000 | $2.5M | 21 Aug 2026 |
| 22 Jun 2026 | Archbold Brian David, Officer | 2,516 | $225.2K | 22 Jun 2026 |
| 22 Jun 2026 | Sakys John, Officer | 2,827 | $253.0K | 22 Jun 2026 |
| 16 Jun 2026 | Archbold Brian David, Officer | 1,151 | $116.6K | 16 Jun 2026 |
| 16 Jun 2026 | Sakys John, Officer | 1,223 | $123.8K | 16 Jun 2026 |
| 16 Jun 2026 | Owens Gary M, Former Officer | 3,706 | $375.3K | 16 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 7.9% | 443.7K |
| 9 Oct 2026 | Wasatch Advisors LP | 13G | 6.9% | 387.1K |
| 7 Jul 2026 | Long Path Smaller Companies Fund, LP | 13G amended | 8.6% | 477.1K |
| 15 Apr 2026 | Long Path Smaller Companies Fund, LP | 13G amended | 7.3% | 405.6K |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 13 Mar 2026 | Long Path Smaller Companies Fund, LP | 13G | 5.6% | 311.7K |
| 31 Oct 2025 | The Vanguard Group | 13G amended | 5.84% | 321.7K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 390.6K | -12.64% | 3.83 |
| 30 Sep 2026 | 447.0K | +10.78% | 3.7 |
| 15 Sep 2026 | 403.6K | -7.01% | 3.02 |
| 31 Aug 2026 | 434.0K | +28.5% | 2.72 |
| 14 Aug 2026 | 337.7K | +4.21% | 1.99 |
| 31 Jul 2026 | 324.1K | +18.21% | 2.5 |
| 15 Jul 2026 | 274.2K | -0.72% | 1.21 |
| 30 Jun 2026 | 276.2K | +15.46% | 1.32 |
Funds that hold it
From each fund's latest Form 13F.
177 funds held it at 30 Jun 2026: 91 added and 38 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Long Path Partners LP | 477,126 | $47.5M | +71,543 |
| BlackRock, Inc. | 440,552 | $43.9M | +46,701 |
| Boston Partners | 265,149 | $26.4M | -3,562 |
| Vanguard Capital Management LLC | 237,457 | $23.6M | +4,814 |
| AQR Capital Management LLC | 203,739 | $20.3M | +33,177 |
| Ranger Investment Management, L.P. | 173,988 | $17.3M | -28,915 |
| Morgan Stanley | 156,979 | $15.6M | -5,137 |
| Diamond Hill Capital Management, LLC (Investment Advisor) | 155,771 | $15.5M | +469 |
| Raymond James Financial Inc. | 149,937 | $14.9M | +27,026 |
| Dimensional Fund Advisors LP | 148,395 | $14.8M | +23,765 |
Peers
Companies in the same industry.
- Danaher Corp. (DHR): revenue $25.6B, market value $166.7B
- AMETEK Inc. (AME): revenue $7.9B, market value $57.7B
- Keysight Technologies, Inc. (KEYS): revenue $6.6B, market value $56.2B
- Roper Technologies Inc. (ROP): revenue $8.3B, market value $44.5B
- Fortive Corp. (FTV): revenue $4.4B, market value $19.6B
- MKS Inc. (MKSI): revenue $4.3B, market value $14.6B
- Cognex Corp. (CGNX): revenue $1.1B, market value $9.9B
- Ralliant Corp. (RAL): revenue $2.2B, market value $7.8B
- Sensata Technologies Holding plc (ST): revenue $3.8B, market value $6.0B